scholarly journals Modeling determinants of satisfaction with health care in youth with inflammatory bowel disease: a cross-sectional survey

2018 ◽  
Vol Volume 10 ◽  
pp. 1289-1305 ◽  
Author(s):  
Antje Timmer ◽  
Dominik de Sordi ◽  
Elise Menke ◽  
Jenny Peplies ◽  
Martin Claßen ◽  
...  
Keyword(s):  
Health Care ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Determinants Of Satisfaction ◽  
Inflammatory Bowel

Therapy experiences and preferences among patients with anemia: Results of a cross-sectional survey among Italian patients with inflammatory bowel disease

2017 ◽  
Vol 49 (10) ◽  
pp. 1098-1103
Author(s):  
Sonja Milovanovic ◽  
Franco Scaldaferri ◽  
Stefania Canarecci ◽  
Flavia Kheiraoui ◽  
Giulia Ciancarella ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Inflammatory Bowel

scholarly journals A cross-sectional survey of multi-generation inflammatory bowel disease consanguinity and its relationship with disease onset

2017 ◽  
Vol 23 (6) ◽  
pp. 337 ◽  
Author(s):  
Mahmoud Mosli ◽  
Abdulelah Alzahrani ◽  
Showlag Showlag ◽  
Abdullah Alshehri ◽  
Ahmed Hejazi ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Disease Onset ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Inflammatory Bowel

scholarly journals A Cross-Sectional Survey on the Transitional Care of Adolescents with Inflammatory Bowel Disease in Hungary

2020 ◽  
Vol 55 ◽  
pp. e279-e285
Author(s):  
Adrienn Erős ◽  
Gábor Veres ◽  
András Tárnok ◽  
Dóra Dohos ◽  
Caroline Otto ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Transitional Care ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Inflammatory Bowel

scholarly journals Home Infusions for Inflammatory Bowel Disease are Safe: United States Experience and Patient Perspectives

2021 ◽  
Author(s):  
Bharati Kochar ◽  
Yue Jiang ◽  
Wenli Chen ◽  
Yuting Bu ◽  
Edward L Barnes ◽  
...  
Keyword(s):  
United States ◽  
Inflammatory Bowel Disease ◽  
Patient Experience ◽  
Bowel Disease ◽  
The United States ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Increased Risk ◽  
Inflammatory Bowel ◽  
States Experience

Abstract Background Home-infusions (HI) for biologic medications are an option for inflammatory bowel disease (IBD) patients in the United States (US). We aimed to describe the population receiving HI and report patient experience with HI. Methods We conducted a retrospective cohort study in the Quintiles-IMSLegacy PharMetrics Adjudicated Claims Database from 2010-2016 to describe the population receiving infliximab and vedolizumab HI and determine predictors for an urgent/emergent visit post-HI. We then administered a cross-sectional survey to IBD-Partners Internet-based cohort participants to assess knowledge and experience with infusions. Results We identified claims for 11,892 conventional infliximab patients, 1,573 home infliximab patients, 438 conventional vedolizumab patients and 138 home vedolizumab patients. There were no differences in demographics or median charges with infliximab home and conventional infusions. Home vedolizumab infusions had a greater median charge than conventional vedolizumab infusion. Less than 4% of patients had an urgent/emergent visit post-HI. Charlson comorbidity index >0 (OR:1.95, 95% CI:1.01-3.77) and Medicaid (OR:3.01, 95%CI:1.53-5.94) conferred significantly higher odds of urgent/emergent visit post-HI. In IBD-Partners, 644 IBD patients responded; 56 received HI. The majority chose HI to save time and preferred HI to conventional infusions. Only 2 patients reported an urgent/emergent visit for HI-related problems. Conclusions HI appears to be safe in IBD patients receiving infliximab and vedolizumab. However, patients with fewer resources and more co-morbidities are at increased risk for an urgent/emergent visit post-HI. The overall patient experience with HI is positive. Expansion of HI may result in decreased therapy-related logistic burden for carefully selected patients.

scholarly journals Impact of Diet on Inflammatory Bowel Disease Symptoms: An Adolescent Viewpoint

2020 ◽  
Vol 2 (4) ◽  
Author(s):  
Megan T Zangara ◽  
Natalie Bhesania ◽  
Wei Liu ◽  
Gail A M Cresci ◽  
Jacob A Kurowski ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Dietary Habits ◽  
Diet Therapy ◽  
Dietary Modification ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Disease Symptoms ◽  
Inflammatory Bowel ◽  
Active Disease

Abstract Background Dietary modification shows promise as therapy in inflammatory bowel disease (IBD); however, it is unknown whether adolescents are interested in a dietary approach. Methods Cross-sectional survey of adolescents with IBD ages 14–21 on disease knowledge, dietary habits, and perceptions of diet therapy. Results A total of 132 subjects (48.5% female), mean age of 17.8 years and median disease length of 5 years (range 0, 16), completed the survey. Diet was perceived as a symptom trigger by 59.8% of subjects, and 45.4% had tried using diet as a treatment for symptom resolution, often without physician supervision and with limited success. Subjects experiencing active disease symptoms as determined by Manitoba IBD Index were more likely to be currently modifying their diet compared to subjects without active disease symptoms (odds ratio = 4.11, confidence interval = 1.58, 10.73, P = 0.003). Conclusions Adolescents with IBD perceive a relationship between diet and disease symptoms and are interested in dietary modification as a symptom management option.

Cannabis use of patients with inflammatory bowel disease in Germany: a cross-sectional survey

2021 ◽  
Author(s):  
Tanja Neufeld ◽  
Katrin Pfuhlmann ◽  
Beate Stock-Schröer ◽  
Lana Kairey ◽  
Nina Bauer ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Black Market ◽  
Cannabis Use ◽  
Medical Cannabis ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Data Set ◽  
Inflammatory Bowel ◽  
New Applications

Abstract Background and Aims Progressive legalization and increasing utilization of medical cannabis open up potential new applications, including for inflammatory bowel disease (IBD). This study aimed to collect current figures on the use of and experience with cannabis among IBD patients in Germany. Methods A 71-item questionnaire was mailed to a randomly selected representative sample of 1000 IBD patients. Results Questionnaires were returned by 417 patients (mean age 49.1 ± 17.0 years; 55.8 % women; 43.4 % ulcerative colitis and 54.7 % Crohn’s disease). Seventy-three respondents (17.5 %) stated past cannabis use for recreational purposes, while 12 users mentioned usage at the time the questionnaire was completed (2.9 %). Seventeen patients (4.1 %) indicated past use of cannabis, and 18 participants (4.3 %) reported current use of cannabis to treat IBD. Perceived benefits of cannabis use by its users included reduced abdominal pain, improved sleep quality, and relief of unease and worry. They reported lower quality of life and higher levels of anxiety or depression than non-users. Of notice, 52.9 % of cannabis users obtained their cannabis from the black market. A total of 76.5 % of former and 50 % of current users did not report their cannabis use to the physician. Conclusion This survey reveals the largest data set on cannabis use among IBD patients in Germany, with the potential for further research. Cannabis is mainly procured from the black market, with unknown quality.

Sign in / Sign up

Export Citation Format

Share Document